- Chordoma treatment involves a multidisciplinary approach including surgery, radiation therapy, and emerging targeted therapies aimed at managing this rare, slow-growing malignant bone tumor, most commonly found along the spine and skull base. Increasing clinical awareness and access to advanced imaging and diagnostic tools are enhancing early detection and treatment efficacy
- The escalating demand for chordoma treatment is primarily fueled by the growing prevalence of rare cancers, increased research focus on orphan diseases, and advancements in precision oncology that offer more effective and personalized treatment options
- North America dominated the chordoma treatment market with the largest revenue share of 41.8% in 2024, driven by a robust healthcare infrastructure, high healthcare spending, and the presence of leading research institutions conducting clinical trials and developing novel therapies, particularly in the U.S. where patient advocacy and rare disease funding play key roles
- Asia-Pacific is expected to be the fastest growing region in the chordoma treatment market during the forecast period due to increasing healthcare investments, improved access to specialized cancer care, and rising awareness of rare diseases
- The targeted therapy segment dominated the chordoma treatment market with a market share of 46.2% in 2024, propelled by the growing availability of molecular diagnostics and the effectiveness of precision treatments such as tyrosine kinase inhibitors in managing chordoma
